



About us

Deltamune, with a history dating back to 1977, is a Gauteng based South African company focusing on veterinary public health. Inactivated vaccines focusing on South African strains have been produced since 1980. The development of ELISA tests for various poultry diseases commenced in 1985. At Deltamune we support our customers to

achieve their production goals, backed by state of the art vaccines research and development, manufacture of biological products. Supported by an ISO 17025 (SANAS V.0007) accredited and Department of Agriculture, Forestry and Fisheries (DAFF) approved test laboratory.

Product Range and Capabilities

	Avian Influenza (AI)	E.coli	E.coli 0157	Egg Drop Syndrome (EDS)	Fowl Pox	Infectious Bronchitis (IB)	Infectious Bursal (IBD)	Infectious Coryza (COR)	M. gallisepticum (MG)	Newcastle Disease (ND)	Ornithobacterium rhinotracheale (OR)	Pasteurella multocida (PM)	Pigeon Pox	Salmonella Enteritidis (SE)	Salmonella Gallinarum (SG)	Salmonella Infantis (SI)	Salmonella Muenchen (SM)	Salmonella Typhimurium (ST)	
Registered Products	AVIVAC® AI	X																	
	AVIVAC® COR/EDS			X				X											
	AVIVAC® CORYZA							X											
	AVIVAC® ND									X									
	AVIVAC® SE													X					
	STRUVAC ND PLUS									X									
	Autogenous vaccine solutions provided through veterinarians include:	X	X		X	X	X	X	X		X	X	X	X	X	X	X	X	X
	Vaccine support products																		

Contact us for solutions to your vaccination and laboratory needs

Email: info@deltamune.co.za Website: www.deltamune.co.za
 Telephone: +27 (0)12 664 5730 Fax: +27 (0)12 664 5149

Registration holder: DELTAMUNE (PTY) LTD Reg.1994/005981/07
 AVIVAC® SE is distributed by: Immuno-Vet Services CC (Reg. No. 1988/025418/23)
 Telephone: +27 (0)11 699-6240 Fax: +27 (0)11 462 0869
 Website: www.immunovet.co.za Email: info@immunovet.co.za



AVIVAC® SE

Reg. No. G 2055 Act 36/1947

A South African derived SE vaccine with proven benefits to humans and fowls

An oil-emulsion of inactivated *Salmonella* Enteritidis.



What is *Salmonella* Enteritidis?

Salmonella Enteritidis is a contagious animal disease caused by a bacterium and characterised by septicaemia in young poultry and a carrier state in older poultry. The control of *Salmonella* Enteritidis in commercial broilers or layers is most important as there are human health considerations (zoonosis), as well as economic considerations for the poultry producer. It is thus essential that control measures are meticulously followed to ensure that outbreaks and shedding of organisms do not occur in commercial broiler and layer flocks.

Effective immunisation with a suitable vaccine forms only part of a comprehensive *Salmonella*

reduction plan which also entails strict biosecurity measures with an appropriate *Salmonella* monitoring plan in place.


Development of this vaccine was done according to GLP guidelines and animal studies performed following GCP guidelines. Manufacturing of the vaccine is conducted in a facility that adheres to European GMP guidelines, with virus propagated in specific pathogen free (SPF) embryonated chicken eggs. Sterility testing is performed in the Deltamune ISO 17025 accredited laboratory (SANAS V.0007: VAC-QCD-ME-019 method).

Advantages of using AVIVAC® SE

- **Reduced mortalities**
- **Reduced drop in egg production**
- **Reduction in the isolation of SE** from organs
- **South African isolate used** as base of the vaccine
- Oil adjuvated vaccine ensures **high immune response and long duration of immunity**
- **World-class technical and laboratory support** for the product provided by Deltamune

AVIVAC® SE is indicated for preventive immunisation of breeders and replacement pullets against *Salmonella* Enteritidis. Vaccination with AVIVAC® SE leads to a reduction of mortalities, less drop in egg production and a reduction in the isolation of *Salmonella* Enteritidis from organs of vaccinated fowls challenged with field strains of *Salmonella* Enteritidis.


AVIVAC® SE significantly reduces egg production losses in challenge groups*




*Independent study conducted by the Poultry Reference Laboratory (University of Pretoria)

- **All vaccines produced are tested for safety in chickens at double the recommended dosage**
- **Maximum safety ensured during manufacturing process with double sterility testing**


AVIVAC® SE improves survival rate by 66% and reduces morbidity by 89% in challenged fowls



AVIVAC® SE severely restricts the presence of *Salmonella* Enteritidis in the organs of challenged birds



AVIVAC® SE administration monitoring can be performed with ELISA test



Recommended dosage

A dose of 0,5 ml should be injected intramuscularly into the breast muscle of replacement pullets or breeding fowls older than 6 weeks of age. A booster vaccination must be administered at least 4 weeks after the first one, but not within 4 weeks of onset of lay.